A New Breath: Aygün’s Lung Transplant and Organ Donation Story | PEP Talk Transcript

Hello, my name is Aygün. I am breathing today with the lungs of a deceased person who donated five vital organs. I am endlessly grateful—truly, a thousand times grateful—to my late donor and to the generous family who donated their organs. I was born with lung disease. It continued throughout my childhood and into adulthood. Although […]

A New Breath: Aygün’s Lung Transplant and Organ Donation Story | PEP Talk Transcript Read Post »

Factors influencing treatment decisions in patients with pulmonary arterial hypertension, Deutsche Medizinische Wochenschrift, September 9, 2026

An article recently published in the Deutsche Medizinische Wochenschrift reported on a multicentre, non-interventional study of 79 patients who started pulmonary arterial hypertension therapy ≤12 months prior to study inclusion. Data available per routine clinical practice were collected. Furthermore, physician’s rationale for treatment decision was assessed. Key findings: A patient’s risk level was the main

Factors influencing treatment decisions in patients with pulmonary arterial hypertension, Deutsche Medizinische Wochenschrift, September 9, 2026 Read Post »

Randomised, controlled trial on fluid restriction in pulmonary arterial hypertension, Respiration, September 9, 2026

A prospective, randomised, controlled single-centre study looking at whether fluid restriction (FR) helps pulmonary arterial hypertension patients with right heart failure and signs of volume overload. 41 patients (average age 70, mostly World Health Organisation (WHO) Functional class III, were split between intensified fluid restriction counselling (around 1.5 litres per day) and routine fluid restriction

Randomised, controlled trial on fluid restriction in pulmonary arterial hypertension, Respiration, September 9, 2026 Read Post »

The French Pulmonary Hypertension Associations celebrates its 30th anniversary at its 6th Patient Congress on 13-15 November 2026

The French Pulmonary Hypertension Association HTaPFrance is holding its 6th Patient Congress, 13–15 November 2026 at Centre Valpré in Écully, France — coinciding with the association’s 30th anniversary. The congress is open to pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH patients, those awaiting or having received a transplant, along with their families,

The French Pulmonary Hypertension Associations celebrates its 30th anniversary at its 6th Patient Congress on 13-15 November 2026 Read Post »

Pulmovant announces positive topline results from its Phase 2 PHocus trial of mosliciguat in pulmonary hypertension associated with interstitial lung disease (PH-ILD)

The findings of the Pulmovant Phase 2 PHocus trial of mosliciguat in pulmonary hypertension associated with interstitial lung disease (PH-ILD, Group 3 of the World Health Organisation, WHO, pulmonary hypertension classification) were presented on September 8, 2026, at the European Respiratory Society (ERS) International Congress 2026 by Marc Humbert, MD, PhD, Professor of Respiratory Medicine

Pulmovant announces positive topline results from its Phase 2 PHocus trial of mosliciguat in pulmonary hypertension associated with interstitial lung disease (PH-ILD) Read Post »

Breaking news! The European Respiratory Society (ERS) Clinical Practice Guidelines update for Pulmonary Arterial Hypertension (PAH) presented today at the ERS Congress in Barcelona, September 7, 2026

The European Respiratory Society (ERS) Clinical Practice Guidelines update for Pulmonary Arterial Hypertension (PAH) were presented today at the ERS Congress! The Alliance for Pulmonary Hypertension Vice President Louise Bouman – van der Waal was at the congress and attended this important session. Here is the link to the article: https://lnkd.in/evX7wHhe Pisana Ferrari, President of

Breaking news! The European Respiratory Society (ERS) Clinical Practice Guidelines update for Pulmonary Arterial Hypertension (PAH) presented today at the ERS Congress in Barcelona, September 7, 2026 Read Post »

Pulnovo Medical Announces Results of the PADN-HF-PH Trial at ESC Congress 2026, Simultaneously Published in The New England Journal of Medicine (NEJM), September 3, 2026

Pulnovo Medical‘s PADN-HF-PH trial results were presented at European Society of Cardiology (ESC) Congress 2026 in Munich, Germany, and published simultaneously in a New England Journal of Medicine article. The multicenter, randomized trial enrolled 264 patients with pulmonary hypertension associated with left heart disease (pulmonary hypertension associated with left heart disease (PH-LHD), World Health Organisation

Pulnovo Medical Announces Results of the PADN-HF-PH Trial at ESC Congress 2026, Simultaneously Published in The New England Journal of Medicine (NEJM), September 3, 2026 Read Post »

On 19th September, pulmonary hypertension nurses Iain Armstrong and Javier Jimenez are taking the plunge for patients for “Swim Serpentine”, covering 1,609 metres, in London’s Hyde Park

On 19th September, pulmonary hypertension nurses Iain Armstrong (Chairman of the UK pulmonary Hypertension association), and Javier Jimenez will spend one mile experiencing what their patients face every single day. They will swim in the open water of London’s Hyde Park for Swim Serpentine, covering 1,609 metres in the heart of the city. The shock

On 19th September, pulmonary hypertension nurses Iain Armstrong and Javier Jimenez are taking the plunge for patients for “Swim Serpentine”, covering 1,609 metres, in London’s Hyde Park Read Post »

A familiar drug in unfamiliar territory: Will we manage to repurpose SGLT2 inhibitors in pulmonary arterial hypertension?, Journal of Heart and Lung Transplant, September 3, 2026

The September issue of Journal of Heart and Lung Transplant presents new data pointing to sodium-glucose cotransporter 2 (SGLT2) inhibitors — drugs like dapagliflozin and empagliflozin, originally developed for diabetes — as a potential novel avenue for treating pulmonary arterial hypertension. Initially valued for their effect on kidney glucose reabsorption, sodium-glucose cotransporter 2 (SGLT2) inhibitors

A familiar drug in unfamiliar territory: Will we manage to repurpose SGLT2 inhibitors in pulmonary arterial hypertension?, Journal of Heart and Lung Transplant, September 3, 2026 Read Post »

Reduced brain blood flow, heart strain, and cognitive symptoms in pulmonary arterial hypertension, Therapeutic Advances in Respiratory Diseases, Jan-Dec 2026

Some patients with pulmonary arterial hypertension experience difficulties with memory, thinking, or mood. A group of Chinese researchers have investigated whether reduced blood flow to the brain is connected to heart strain and disease severity. They compared brain scans from 30 people with pulmonary arterial hypertension and 51 healthy individuals matched for age and sex.

Reduced brain blood flow, heart strain, and cognitive symptoms in pulmonary arterial hypertension, Therapeutic Advances in Respiratory Diseases, Jan-Dec 2026 Read Post »

Pulmonary hypertension associated with interstitial lung disease: a state-of-the-art review, European Respiratory Journal, Vol 68 Issue 1

Following the 7th World Symposium on Pulmonary Hypertension, a review published in the European Respiratory Journal summarises the current understanding of Pulmonary hypertension associated with interstitial lung disease (PH-ILD). It covers the condition’s clinical features, underlying biology, diagnosis, prognosis and treatment, while flagging diagnostic challenges — from overlapping symptoms to the lack of specific biomarkers

Pulmonary hypertension associated with interstitial lung disease: a state-of-the-art review, European Respiratory Journal, Vol 68 Issue 1 Read Post »

What’s new on the Pulmonary Hypertension Knowledge Sharing Platform – August 2026

This month’s news roundup brings together the latest in pulmonary hypertension research and care. On the clinical front, several new studies stand out — from encouraging long-term rehabilitation data in the FONCE-HTAP trial, to new insights into pulmonary artery stiffness, BMPR2 signalling, and exercise safety after pulmonary endarterectomy. On the drug development side, we cover

What’s new on the Pulmonary Hypertension Knowledge Sharing Platform – August 2026 Read Post »

The Pulmonary Vascular Research Institute (PVRI) publishes a 13-part series to help people living with pulmonary hypertension (PH), their families, and carers understand clinical trials,

This series was created by the IDDI Patient Engagement and Empowerment Workstream, of the Pulmonary Vascular Research Institute (PVRI), whose members are Hall Skaara, Louise Bouman, Jamie Myrah, Colleen Brunetti, Luke Howard, Gil Golden, Vera Toth-Fejel, Wendy Gin-Sing. The series explains what clinical trials are, how they work, and what it means to take part. All

The Pulmonary Vascular Research Institute (PVRI) publishes a 13-part series to help people living with pulmonary hypertension (PH), their families, and carers understand clinical trials, Read Post »

Long-term efficacy and safety of rehabilitation in patients with pulmonary arterial hypertension: the FONCE-HTAP randomized controlled trial, Annals of the American Thoracic Society, July 20, 2026

The findings of a multi-center randomized controlled trial investigating the long-term efficiency of rehabilitation in patients with pulmonary arterial hypertension was published in the Annals of the American Thoracic Society on July 20, 2026. The study followed 47 patients with stable pulmonary arterial hypertension across 9 French centers, looking at the long-term impact of a

Long-term efficacy and safety of rehabilitation in patients with pulmonary arterial hypertension: the FONCE-HTAP randomized controlled trial, Annals of the American Thoracic Society, July 20, 2026 Read Post »

Predictive Power of Pulmonary Artery Stiffness – Right Ventricular Interplay, but not Pulmonary Vascular Resistance, in Mild Pulmonary Hypertension: A PVRI GoDeep meta-registry analysis, CHEST, August 26, 2026

In a recent LinkedIn post Prof. Werner Seeger writes that the GoDeep meta-registry analysis about the predictive power of pulmonary artery stiffness – right ventricular interplay in mild pulmonary hypertension (PH) is now online. He reports that in the analysis, notably, parameters integrating pulsatile vascular load and interdependent right ventricular function possess predictive power independent

Predictive Power of Pulmonary Artery Stiffness – Right Ventricular Interplay, but not Pulmonary Vascular Resistance, in Mild Pulmonary Hypertension: A PVRI GoDeep meta-registry analysis, CHEST, August 26, 2026 Read Post »

US Food and Drug Administration (FDA) accepts for review a New Drug Application (NDA) for ralinepag, an investigational prostacyclin IP receptor agonist to treat pulmonary arterial hypertension (PAH), Biospace, August 24, 2026

The US Food and Drug Administration (FDA) has accepted for review a New Drug Application from United Therapeutics Corporation for ralinepag, an investigational prostacyclin IP receptor agonist intended to treat pulmonary arterial hypertension (PAH). The filing rests on results from the Phase III ADVANCE OUTCOMES study See our previous article on this topic here. Read more at

US Food and Drug Administration (FDA) accepts for review a New Drug Application (NDA) for ralinepag, an investigational prostacyclin IP receptor agonist to treat pulmonary arterial hypertension (PAH), Biospace, August 24, 2026 Read Post »

Safety of exercise after pulmonary endarterectomy: a systematic review, European Respiratory Journal Open Research 2026

A systematic review recently published in the European Respiratory Journal Open Research looked at whether early exercise after pulmonary endarterectomy (PEA) surgery in chronic thromboembolic pulmonary hypertension (CTEPH) is safe and feasible, given that post-operative cardiac remodelling needs to be balanced against the benefits of getting moving early. Searching the AMED, CINAHL, Embase, and MEDLINE

Safety of exercise after pulmonary endarterectomy: a systematic review, European Respiratory Journal Open Research 2026 Read Post »

Multicentre study explores impaired bone morphogenetic protein receptor 2 (BMPR2) signalling across pulmonary hypertension subgroups, European Respiratory Journal Open Research 2026

A multicentre study recently published on the European Respiratory Journal Open Research looked at bone morphogenetic protein receptor 2 (BMPR2) signalling — a pathway already known to be disrupted in heritable pulmonary arterial hypertension (PAH) — across a wider range of pulmonary hypertension (PH) patients, to see whether the same disturbance shows up in other

Multicentre study explores impaired bone morphogenetic protein receptor 2 (BMPR2) signalling across pulmonary hypertension subgroups, European Respiratory Journal Open Research 2026 Read Post »

Tenax Therapeutics announces results from phase 3 LEVEL trial of TNX-103 in patients with pulmonary hypertension associated with heart failure with preserved ejection fraction, PH-HFpEF, August 10, 2026

Tenax Therapeutics, Inc. announced today the topline results of its Phase 3 LEVEL trial, which evaluated TNX-103 (oral levosimendan) in patients with pulmonary hypertension associated with heart failure with preserved ejection fraction (PH-HFpEF), Group 2 of the World Health Organisation (WHO) pulmonary hypertension classification. The trial did not meet its primary endpoint — improvement in

Tenax Therapeutics announces results from phase 3 LEVEL trial of TNX-103 in patients with pulmonary hypertension associated with heart failure with preserved ejection fraction, PH-HFpEF, August 10, 2026 Read Post »

Live Webinar on Early Referral for Lung Transplantation: Recognizing the Right Time, CHEST, June 2, 2026, recording now available

A live, case-based webinar held on June 2, 2026 looked at when and how patients with advanced pulmonary disease should be referred for lung transplant evaluation. The expert faculty walked through evidence-based referral criteria, disease-specific considerations, and complex scenarios — including interstitial lung disease, pulmonary arterial hypertension, and critically ill patients in the Intensive Care

Live Webinar on Early Referral for Lung Transplantation: Recognizing the Right Time, CHEST, June 2, 2026, recording now available Read Post »

TRANSLATE »
Scroll to Top